Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Zinecard (Dexrazoxane Hydrochloride),ZinecardStudy001,2021,USA,MDV,350,62,65,35,27.5,22,88,12,15,40,30,15,55,25,15,5,20,45,30,10,3,2,5,4,35,60,45,AC,TC,AC-T,CMF,25,30,20,15,70,55,10,40,50,60,2
Zinecard (Dexrazoxane Hydrochloride),ZinecardStudy002,2022,Canada,Claim Database,420,68,60,40,28.1,25,85,15,18,38,32,12,52,28,14,6,22,43,31,12,4,3,6,5,38,62,48,EC,Taxol,FEC,Docetaxel,28,32,18,18,72,58,12,42,46,62,3
Zinecard (Dexrazoxane Hydrochloride),ZinecardStudy003,2023,UK,MDV,280,70,55,45,29.0,28,82,18,20,35,33,12,50,30,15,5,25,40,30,15,5,4,7,6,40,65,50,CEF,Anthracycline,Taxane,Carboplatin,30,35,15,20,75,60,15,45,40,65,4
